347 related articles for article (PubMed ID: 22570524)
1. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.
Shen LH; Liao MH; Tseng YC
J Biomed Biotechnol; 2012; 2012():259349. PubMed ID: 22570524
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
de Natale ER; Niccolini F; Wilson H; Politis M
Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor mapping with PET imaging in Parkinson's disease.
Niccolini F; Su P; Politis M
J Neurol; 2014 Dec; 261(12):2251-63. PubMed ID: 24627109
[TBL] [Abstract][Full Text] [Related]
4. Radiotracers for imaging of Parkinson's disease.
Abbasi Gharibkandi N; Hosseinimehr SJ
Eur J Med Chem; 2019 Mar; 166():75-89. PubMed ID: 30685535
[TBL] [Abstract][Full Text] [Related]
5. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.
Giza E; Gotzamani-Psarrakou A; Bostantjopoulou S
Hell J Nucl Med; 2012; 15(3):224-32. PubMed ID: 23106055
[TBL] [Abstract][Full Text] [Related]
6. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Thobois S; Guillouet S; Broussolle E
Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
[TBL] [Abstract][Full Text] [Related]
7. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.
Booij J; Tissingh G; Winogrodzka A; van Royen EA
Eur J Nucl Med; 1999 Feb; 26(2):171-82. PubMed ID: 9933352
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography molecular imaging of dopaminergic system in drug addiction.
Hou H; Tian M; Zhang H
Anat Rec (Hoboken); 2012 May; 295(5):722-33. PubMed ID: 22467195
[TBL] [Abstract][Full Text] [Related]
9. [Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
Larisch R; Klimke A
Nuklearmedizin; 1998; 37(7):245-50. PubMed ID: 9830615
[TBL] [Abstract][Full Text] [Related]
10. [Functional imaging in mental disorders].
Borbély K
Orv Hetil; 2004 Feb; 145(6):277-89. PubMed ID: 15038321
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
Mehler-Wex C; Riederer P; Gerlach M
Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of dopaminergic brain imaging in Parkinson's disease.
Seibyl J; Russell D; Jennings D; Marek K
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):4-16. PubMed ID: 22460156
[TBL] [Abstract][Full Text] [Related]
13. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.
Kahraman D; Eggers C; Schicha H; Timmermann L; Schmidt M
J Neurol; 2012 Feb; 259(2):251-60. PubMed ID: 21750954
[TBL] [Abstract][Full Text] [Related]
14. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders.
Guilloteau D; Chalon S
Curr Pharm Des; 2005; 11(25):3237-45. PubMed ID: 16250852
[TBL] [Abstract][Full Text] [Related]
15. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders.
Verhoeff NP
Psychopharmacology (Berl); 1999 Dec; 147(3):217-49. PubMed ID: 10639681
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of the dopaminergic neurotransmission system using [123I]FP-CIT SPECT in 6-OHDA lesioned rats.
Niñerola-Baizán A; Rojas S; Bonastre M; Tudela R; Lomeña F; Pavía J; Marin C; Ros D
Contrast Media Mol Imaging; 2015; 10(1):67-73. PubMed ID: 24888455
[TBL] [Abstract][Full Text] [Related]
17. A Review of Molecular Imaging of Glutamate Receptors.
Kim JH; Marton J; Ametamey SM; Cumming P
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081223
[TBL] [Abstract][Full Text] [Related]
18. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
[TBL] [Abstract][Full Text] [Related]
19. SPECT and PET imaging of the dopaminergic system in Parkinson's disease.
Brücke T; Djamshidian S; Bencsits G; Pirker W; Asenbaum S; Podreka I
J Neurol; 2000 Sep; 247 Suppl 4():IV/2-7. PubMed ID: 11199811
[TBL] [Abstract][Full Text] [Related]
20. SPECT Molecular Imaging in Familial Parkinson's Disease.
Varrone A; Pellecchia MT
Int Rev Neurobiol; 2018; 142():225-260. PubMed ID: 30409254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
